Literature DB >> 15367247

Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?

Hans-Georg Eichler1, Sheldon X Kong, William C Gerth, Panagiotis Mavros, Bengt Jönsson.   

Abstract

BACKGROUND: An increasing number of health-care systems, both public and private, such as managed-care organizations, are adopting results from cost-effectiveness (CE) analysis as one of the measures to inform decisions on allocation of health-care resources. It is expected that thresholds for CE ratios may be established for the acceptance of reimbursement or formulary listing.
OBJECTIVE: This paper provides an overview of the development of and debate on CE thresholds, reviews threshold figures (i.e., cost per unit of health gain) currently proposed for or applied to resource-allocation decisions, and explores how thresholds may emerge. DISCUSSION: At the time of this review, there is no evidence from the literature that any health-care system has yet implemented explicit CE ratio thresholds. The fact that some government agencies have utilized results from CE analysis in pricing/reimbursement decisions allows for retrospective analysis of the consistency of these decisions. As CE analysis becomes more widely utilized in assisting health-care decision-making, this may cause decision-makers to become increasingly consistent.
CONCLUSIONS: When CE analysis is conducted, well-established methodology should be used and transparency should be ensured. CE thresholds are expected to emerge in many countries, driven by the need for transparent and consistent decision-making. Future thresholds will likely be higher in most high-income countries than currently cited rules of thumb.

Mesh:

Year:  2004        PMID: 15367247     DOI: 10.1111/j.1524-4733.2004.75003.x

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  205 in total

1.  Cost-effectiveness of chronic kidney disease mass screening test in Japan.

Authors:  Masahide Kondo; Kunihiro Yamagata; Shu-ling Hoshi; Chie Saito; Koichi Asahi; Toshiki Moriyama; Kazuhiko Tsuruya; Hideaki Yoshida; Kunitoshi Iseki; Tsuyoshi Watanabe
Journal:  Clin Exp Nephrol       Date:  2011-12-14       Impact factor: 2.801

Review 2.  Cinacalcet: a pharmacoeconomic review of its use in secondary hyperparathyroidism in end-stage renal disease.

Authors:  Greg L Plosker
Journal:  Pharmacoeconomics       Date:  2011-09       Impact factor: 4.981

3.  The Irish Cost-Effectiveness Threshold: Does it Support Rational Rationing or Might it Lead to Unintended Harm to Ireland's Health System?

Authors:  James F O'Mahony; Diarmuid Coughlan
Journal:  Pharmacoeconomics       Date:  2016-01       Impact factor: 4.981

4.  Stochastic multi-objective auto-optimization for resource allocation decision-making in fixed-input health systems.

Authors:  Nathaniel D Bastian; Tahir Ekin; Hyojung Kang; Paul M Griffin; Lawrence V Fulton; Benjamin C Grannan
Journal:  Health Care Manag Sci       Date:  2016-01-07

5.  Should the Lambda (λ) Remain Silent?

Authors:  Hossein Haji Ali Afzali; Jonathan Karnon; Mark Sculpher
Journal:  Pharmacoeconomics       Date:  2016-04       Impact factor: 4.981

6.  Cost-Effectiveness of a Comprehensive Approach for Hypertension Control in Low-Income Settings in Argentina: Trial-Based Analysis of the Hypertension Control Program in Argentina.

Authors:  Federico Augustovski; Martín Chaparro; Alfredo Palacios; Lizheng Shi; Andrea Beratarrechea; Vilma Irazola; Adolfo Rubinstein; Katherine Mills; Jiang He; Andrés Pichon Riviere
Journal:  Value Health       Date:  2018-08-30       Impact factor: 5.725

Review 7.  Economic evaluations: a new avenue of outcome assessment in spinal disorders.

Authors:  Nicole van der Roer; Norbert Boos; Maurits W van Tulder
Journal:  Eur Spine J       Date:  2005-12-01       Impact factor: 3.134

Review 8.  Cost effectiveness of therapeutic interventions in ankylosing spondylitis: a critical and systematic review.

Authors:  Cécile Gaujoux-Viala; Bruno Fautrel
Journal:  Pharmacoeconomics       Date:  2012-12-01       Impact factor: 4.981

Review 9.  HPV-related oropharyngeal cancer: a review on burden of the disease and opportunities for prevention and early detection.

Authors:  Mary Roz Timbang; Michael W Sim; Arnaud F Bewley; D Gregory Farwell; Avinash Mantravadi; Michael G Moore
Journal:  Hum Vaccin Immunother       Date:  2019-05-07       Impact factor: 3.452

10.  Cost-effectiveness of helicopter versus ground emergency medical services for trauma scene transport in the United States.

Authors:  M Kit Delgado; Kristan L Staudenmayer; N Ewen Wang; David A Spain; Sharada Weir; Douglas K Owens; Jeremy D Goldhaber-Fiebert
Journal:  Ann Emerg Med       Date:  2013-04-09       Impact factor: 5.721

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.